Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 294

1.

Oncological outcomes following radical prostatectomy for patients with pT4 prostate cancer.

Kaushik D, Boorjian SA, Thompson RH, Eisenberg MS, Carlson RE, Bergstralh EJ, Frank I, Gettman MT, Tollefson MK, Karnes RJ.

Int Braz J Urol. 2016 Nov-Dec;42(6):1091-1098. doi: 10.1590/S1677-5538.IBJU.2016.0290.

2.

Predictors of Incident ESRD among Patients with Primary Hyperoxaluria Presenting Prior to Kidney Failure.

Zhao F, Bergstralh EJ, Mehta RA, Vaughan LE, Olson JB, Seide BM, Meek AM, Cogal AG, Lieske JC, Milliner DS; Investigators of Rare Kidney Stone Consortium.

Clin J Am Soc Nephrol. 2016 Jan 7;11(1):119-26. doi: 10.2215/CJN.02810315. Epub 2015 Dec 10.

3.

Renal hemodynamic effects of the HMG-CoA reductase inhibitors in autosomal dominant polycystic kidney disease.

Zand L, Torres VE, Larson TS, King BF, Sethi S, Bergstralh EJ, Angioi A, Fervenza FC.

Nephrol Dial Transplant. 2016 Aug;31(8):1290-5. doi: 10.1093/ndt/gfv394. Epub 2015 Nov 27.

4.

Stone Composition Among First-Time Symptomatic Kidney Stone Formers in the Community.

Singh P, Enders FT, Vaughan LE, Bergstralh EJ, Knoedler JJ, Krambeck AE, Lieske JC, Rule AD.

Mayo Clin Proc. 2015 Oct;90(10):1356-65. doi: 10.1016/j.mayocp.2015.07.016. Epub 2015 Sep 6.

5.

Altered Calcium and Vitamin D Homeostasis in First-Time Calcium Kidney Stone-Formers.

Ketha H, Singh RJ, Grebe SK, Bergstralh EJ, Rule AD, Lieske JC, Kumar R.

PLoS One. 2015 Sep 2;10(9):e0137350. doi: 10.1371/journal.pone.0137350. eCollection 2015.

6.

The Difficult Ureter: Clinical and Radiographic Characteristics Associated With Upper Urinary Tract Access at the Time of Ureteroscopic Stone Treatment.

Viers BR, Viers LD, Hull NC, Hanson TJ, Mehta RA, Bergstralh EJ, Vrtiska TJ, Krambeck AE.

Urology. 2015 Nov;86(5):878-84. doi: 10.1016/j.urology.2015.08.007. Epub 2015 Aug 20.

PMID:
26299463
7.

Endoscopic and histologic findings in a cohort of uric acid and calcium oxalate stone formers.

Viers BR, Lieske JC, Vrtiska TJ, Herrera Hernandez LP, Vaughan LE, Mehta RA, Bergstralh EJ, Rule AD, Holmes DR 3rd, Krambeck AE.

Urology. 2015 Apr;85(4):771-6. doi: 10.1016/j.urology.2014.12.036. Epub 2015 Feb 11.

8.

Phenotype-Genotype Correlations and Estimated Carrier Frequencies of Primary Hyperoxaluria.

Hopp K, Cogal AG, Bergstralh EJ, Seide BM, Olson JB, Meek AM, Lieske JC, Milliner DS, Harris PC; Rare Kidney Stone Consortium.

J Am Soc Nephrol. 2015 Oct;26(10):2559-70. doi: 10.1681/ASN.2014070698. Epub 2015 Feb 2.

9.

Quantification of asymptomatic kidney stone burden by computed tomography for predicting future symptomatic stone events.

Selby MG, Vrtiska TJ, Krambeck AE, McCollough CH, Elsherbiny HE, Bergstralh EJ, Lieske JC, Rule AD.

Urology. 2015 Jan;85(1):45-50. doi: 10.1016/j.urology.2014.08.031. Epub 2014 Oct 22.

10.

Kidney stones are common after bariatric surgery.

Lieske JC, Mehta RA, Milliner DS, Rule AD, Bergstralh EJ, Sarr MG.

Kidney Int. 2015 Apr;87(4):839-45. doi: 10.1038/ki.2014.352. Epub 2014 Oct 29.

11.

Stone composition as a function of age and sex.

Lieske JC, Rule AD, Krambeck AE, Williams JC, Bergstralh EJ, Mehta RA, Moyer TP.

Clin J Am Soc Nephrol. 2014 Dec 5;9(12):2141-6. doi: 10.2215/CJN.05660614. Epub 2014 Oct 2.

12.

Serum concentrations of prostate-specific antigen measured using immune extraction, trypsin digestion, and tandem mass spectrometry quantification of LSEPAELTDAVK peptide.

Klee EW, Bondar OP, Goodmanson MK, Trushin SA, Bergstralh EJ, Singh RJ, Anderson NL, Klee GG.

Arch Pathol Lab Med. 2014 Oct;138(10):1381-6. doi: 10.5858/arpa.2013-0462-OA.

PMID:
25268201
13.

Nephrocalcinosis is a risk factor for kidney failure in primary hyperoxaluria.

Tang X, Bergstralh EJ, Mehta RA, Vrtiska TJ, Milliner DS, Lieske JC.

Kidney Int. 2015 Mar;87(3):623-31. doi: 10.1038/ki.2014.298. Epub 2014 Sep 17.

14.

Gleason grading after neoadjuvant hormonal therapy retains prognostic value for systemic progression following radical prostatectomy.

Stewart SB, Cheville JC, Sebo TJ, Frank I, Boorjian SA, Thompson RH, Gettman MT, Tollefson MK, Umbriet EC, Psutka SP, Bergstralh EJ, Rangel L, Karnes RJ.

Prostate Cancer Prostatic Dis. 2014 Dec;17(4):332-7. doi: 10.1038/pcan.2014.30. Epub 2014 Aug 26.

PMID:
25156060
15.

Salvage lymph node dissection for prostate cancer nodal recurrence detected by 11C-choline positron emission tomography/computerized tomography.

Karnes RJ, Murphy CR, Bergstralh EJ, DiMonte G, Cheville JC, Lowe VJ, Mynderse LA, Kwon ED.

J Urol. 2015 Jan;193(1):111-6. doi: 10.1016/j.juro.2014.08.082. Epub 2014 Aug 20.

PMID:
25150640
16.

The ROKS nomogram for predicting a second symptomatic stone episode.

Rule AD, Lieske JC, Li X, Melton LJ 3rd, Krambeck AE, Bergstralh EJ.

J Am Soc Nephrol. 2014 Dec;25(12):2878-86. doi: 10.1681/ASN.2013091011. Epub 2014 Aug 7.

17.

Gastric bypass surgery and measured and estimated GFR in women.

Lieske JC, Collazo-Clavell ML, Sarr MG, Rule AD, Bergstralh EJ, Kumar R.

Am J Kidney Dis. 2014 Oct;64(4):663-5. doi: 10.1053/j.ajkd.2014.06.016. Epub 2014 Jul 29. No abstract available.

18.

Comparison of biochemical failure rates between permanent prostate brachytherapy and radical retropubic prostatectomy as a function of posttherapy PSA nadir plus 'X'.

Ahmed KA, Davis BJ, Mynderse LA, Slezak JM, Bergstralh EJ, Wilson TM, Choo CR.

Radiat Oncol. 2014 Jul 29;9:171. doi: 10.1186/1748-717X-9-171.

19.

Primary Gleason grade 4 at the positive margin is associated with metastasis and death among patients with Gleason 7 prostate cancer undergoing radical prostatectomy.

Viers BR, Sukov WR, Gettman MT, Rangel LJ, Bergstralh EJ, Frank I, Tollefson MK, Thompson RH, Boorjian SA, Karnes RJ.

Eur Urol. 2014 Dec;66(6):1116-24. doi: 10.1016/j.eururo.2014.07.004. Epub 2014 Jul 19.

PMID:
25052213
20.

Extended antimicrobial use in patients undergoing percutaneous nephrolithotomy and associated antibiotic related complications.

Viers BR, Cockerill PA, Mehta RA, Bergstralh EJ, Krambeck AE.

J Urol. 2014 Dec;192(6):1667-72. doi: 10.1016/j.juro.2014.06.090. Epub 2014 Jul 3.

PMID:
24998482
21.

Thiazide diuretic prophylaxis for kidney stones and the risk of diabetes mellitus.

Singh P, Knoedler JJ, Krambeck AE, Lieske JC, Bergstralh EJ, Rule AD.

J Urol. 2014 Dec;192(6):1700-4. doi: 10.1016/j.juro.2014.06.078. Epub 2014 Jun 30.

22.

Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials.

Irazabal MV, Rangel LJ, Bergstralh EJ, Osborn SL, Harmon AJ, Sundsbak JL, Bae KT, Chapman AB, Grantham JJ, Mrug M, Hogan MC, El-Zoghby ZM, Harris PC, Erickson BJ, King BF, Torres VE; CRISP Investigators.

J Am Soc Nephrol. 2015 Jan;26(1):160-72. doi: 10.1681/ASN.2013101138. Epub 2014 Jun 5.

23.

Sustained pyridoxine response in primary hyperoxaluria type 1 recipients of kidney alone transplant.

Lorenz EC, Lieske JC, Seide BM, Meek AM, Olson JB, Bergstralh EJ, Milliner DS.

Am J Transplant. 2014 Jun;14(6):1433-8. doi: 10.1111/ajt.12706. Epub 2014 May 2.

24.

Derivation of urine output thresholds that identify a very high risk of AKI in patients with septic shock.

Leedahl DD, Frazee EN, Schramm GE, Dierkhising RA, Bergstralh EJ, Chawla LS, Kashani KB.

Clin J Am Soc Nephrol. 2014 Jul;9(7):1168-74. doi: 10.2215/CJN.09360913. Epub 2014 May 1.

25.

The association of tumor volume with mortality following radical prostatectomy.

Knoedler JJ, Karnes RJ, Thompson RH, Rangel LJ, Bergstralh EJ, Boorjian SA.

Prostate Cancer Prostatic Dis. 2014 Jun;17(2):144-8. doi: 10.1038/pcan.2013.61. Epub 2014 Jan 28.

PMID:
24469091
26.

Biomedical system dynamics to improve anemia control with darbepoetin alfa in long-term hemodialysis patients.

McCarthy JT, Hocum CL, Albright RC, Rogers J, Gallaher EJ, Steensma DP, Gudgell SF, Bergstralh EJ, Dillon JC, Hickson LJ, Williams AW, Dingli D.

Mayo Clin Proc. 2014 Jan;89(1):87-94. doi: 10.1016/j.mayocp.2013.10.022.

PMID:
24388026
27.

A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy.

Ross AE, Feng FY, Ghadessi M, Erho N, Crisan A, Buerki C, Sundi D, Mitra AP, Vergara IA, Thompson DJ, Triche TJ, Davicioni E, Bergstralh EJ, Jenkins RB, Karnes RJ, Schaeffer EM.

Prostate Cancer Prostatic Dis. 2014 Mar;17(1):64-9. doi: 10.1038/pcan.2013.49. Epub 2013 Oct 22.

28.

Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy.

Erho N, Crisan A, Vergara IA, Mitra AP, Ghadessi M, Buerki C, Bergstralh EJ, Kollmeyer T, Fink S, Haddad Z, Zimmermann B, Sierocinski T, Ballman KV, Triche TJ, Black PC, Karnes RJ, Klee G, Davicioni E, Jenkins RB.

PLoS One. 2013 Jun 24;8(6):e66855. doi: 10.1371/journal.pone.0066855. Print 2013.

29.

Effect of metformin on prostate cancer outcomes after radical prostatectomy.

Kaushik D, Karnes RJ, Eisenberg MS, Rangel LJ, Carlson RE, Bergstralh EJ.

Urol Oncol. 2014 Jan;32(1):43.e1-7. doi: 10.1016/j.urolonc.2013.05.005. Epub 2013 Jun 28.

30.

Current computed tomography techniques can detect duct of Bellini plugging but not Randall's plaques.

Krambeck AE, Lieske JC, Li X, Bergstralh EJ, Rule AD, Holmes D 3rd, McCollough CM, Vrtiska TJ.

Urology. 2013 Aug;82(2):301-6. doi: 10.1016/j.urology.2013.04.028. Epub 2013 Jun 20.

31.

Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population.

Karnes RJ, Bergstralh EJ, Davicioni E, Ghadessi M, Buerki C, Mitra AP, Crisan A, Erho N, Vergara IA, Lam LL, Carlson R, Thompson DJ, Haddad Z, Zimmermann B, Sierocinski T, Triche TJ, Kollmeyer T, Ballman KV, Black PC, Klee GG, Jenkins RB.

J Urol. 2013 Dec;190(6):2047-53. doi: 10.1016/j.juro.2013.06.017. Epub 2013 Jun 11.

32.

Risk stratification of patients with extraprostatic extension and negative lymph nodes at radical prostatectomy: identifying optimal candidates for adjuvant therapy.

Eisenberg MS, Karnes RJ, Kaushik D, Rangel L, Bergstralh EJ, Boorjian SA.

J Urol. 2013 Nov;190(5):1735-41. doi: 10.1016/j.juro.2013.05.053. Epub 2013 May 29.

PMID:
23727312
33.

Phenotypic characterization of kidney stone formers by endoscopic and histological quantification of intrarenal calcification.

Linnes MP, Krambeck AE, Cornell L, Williams JC Jr, Korinek M, Bergstralh EJ, Li X, Rule AD, McCollough CM, Vrtiska TJ, Lieske JC.

Kidney Int. 2013 Oct;84(4):818-25. doi: 10.1038/ki.2013.189. Epub 2013 May 22.

34.

The presence of extracapsular extension is associated with an increased risk of death from prostate cancer after radical prostatectomy for patients with seminal vesicle invasion and negative lymph nodes.

Mikel Hubanks J, Boorjian SA, Frank I, Gettman MT, Houston Thompson R, Rangel LJ, Bergstralh EJ, Jeffrey Karnes R.

Urol Oncol. 2014 Jan;32(1):26.e1-7. doi: 10.1016/j.urolonc.2012.09.002. Epub 2013 Feb 6.

PMID:
23395235
35.

BMI1, stem cell factor acting as novel serum-biomarker for Caucasian and African-American prostate cancer.

Siddique HR, Parray A, Zhong W, Karnes RJ, Bergstralh EJ, Koochekpour S, Rhim JS, Konety BR, Saleem M.

PLoS One. 2013;8(1):e52993. doi: 10.1371/journal.pone.0052993. Epub 2013 Jan 7. Erratum in: PLoS One. 2013;8(6). doi:10.1371/annotation/d612ee51-4c8e-4468-8373-3d4c503f0da5.

36.

Interaction of adjuvant androgen deprivation therapy with patient comorbidity status on overall survival after radical prostatectomy for high-risk prostate cancer.

Linder BJ, Boorjian SA, Umbreit EC, Carlson RE, Rangel LJ, Bergstralh EJ, Karnes RJ.

Int J Urol. 2013 Aug;20(8):798-805. doi: 10.1111/iju.12047. Epub 2012 Dec 20.

37.

Effect of age on the clinical presentation of incident symptomatic urolithiasis in the general population.

Krambeck AE, Lieske JC, Li X, Bergstralh EJ, Melton LJ 3rd, Rule AD.

J Urol. 2013 Jan;189(1):158-64. doi: 10.1016/j.juro.2012.09.023. Epub 2012 Nov 16.

38.

The impact of clinical stage on prostate cancer survival following radical prostatectomy.

Tollefson MK, Karnes RJ, Rangel LJ, Bergstralh EJ, Boorjian SA.

J Urol. 2013 May;189(5):1707-12. doi: 10.1016/j.juro.2012.11.065. Epub 2012 Nov 15.

PMID:
23159265
39.

Natural history of biochemical recurrence after radical prostatectomy with adjuvant radiation therapy.

Boorjian SA, Tollefson MK, Thompson RH, Rangel LJ, Bergstralh EJ, Karnes RJ.

J Urol. 2012 Nov;188(5):1761-6. doi: 10.1016/j.juro.2012.07.037. Epub 2012 Sep 19.

PMID:
22998913
40.

Somatostatin analog therapy for severe polycystic liver disease: results after 2 years.

Hogan MC, Masyuk TV, Page L, Holmes DR 3rd, Li X, Bergstralh EJ, Irazabal MV, Kim B, King BF, Glockner JF, Larusso NF, Torres VE.

Nephrol Dial Transplant. 2012 Sep;27(9):3532-9. doi: 10.1093/ndt/gfs152. Epub 2012 Jul 6.

41.

Urolithiasis and the risk of ESRD.

El-Zoghby ZM, Lieske JC, Foley RN, Bergstralh EJ, Li X, Melton LJ 3rd, Krambeck AE, Rule AD.

Clin J Am Soc Nephrol. 2012 Sep;7(9):1409-15. Epub 2012 Jun 28.

42.

Temporal trends in incidence of kidney stones among children: a 25-year population based study.

Dwyer ME, Krambeck AE, Bergstralh EJ, Milliner DS, Lieske JC, Rule AD.

J Urol. 2012 Jul;188(1):247-52. doi: 10.1016/j.juro.2012.03.021. Epub 2012 May 15.

43.

Preoperative estimated glomerular filtration rate predicts overall mortality in patients undergoing radical prostatectomy.

Tollefson MK, Boorjian SA, Gettman MT, Rangel LJ, Bergstralh EJ, Karnes RJ.

Urol Oncol. 2013 Nov;31(8):1483-8. doi: 10.1016/j.urolonc.2012.03.014. Epub 2012 May 10.

PMID:
22578510
44.

A prospective, controlled phase II study of neoadjuvant exisulind therapy before radical prostatectomy: effect on apoptosis.

Weight CJ, Kim SP, Karnes RJ, Bergstralh EJ, Cheville JC, Leibovich BC.

Urology. 2012 Aug;80(2):484.e17-22. doi: 10.1016/j.urology.2012.02.027. Epub 2012 Apr 13.

PMID:
22503761
45.

Candidate serum biomarkers for prostate adenocarcinoma identified by mRNA differences in prostate tissue and verified with protein measurements in tissue and blood.

Klee EW, Bondar OP, Goodmanson MK, Dyer RB, Erdogan S, Bergstralh EJ, Bergen HR 3rd, Sebo TJ, Klee GG.

Clin Chem. 2012 Mar;58(3):599-609. doi: 10.1373/clinchem.2011.171637. Epub 2012 Jan 12.

46.

Shock wave lithotripsy and diabetes mellitus: a population-based cohort study.

de Cógáin M, Krambeck AE, Rule AD, Li X, Bergstralh EJ, Gettman MT, Lieske JC.

Urology. 2012 Feb;79(2):298-302. doi: 10.1016/j.urology.2011.07.1430. Epub 2011 Nov 16.

47.

Does body mass index "dilute" the predictive property of prostate-specific antigen for tumor volume at radical prostatectomy?

Mitchell CR, Umbreit EC, Rangel LJ, Bergstralh EJ, Karnes RJ.

Urology. 2011 Oct;78(4):868-72. doi: 10.1016/j.urology.2011.05.060. Epub 2011 Aug 16.

PMID:
21843902
48.

Clinicopathological predictors of systemic progression and prostate cancer mortality in patients with a positive surgical margin at radical prostatectomy.

Boorjian SA, Tollefson MK, Rangel LJ, Bergstralh EJ, Karnes RJ.

Prostate Cancer Prostatic Dis. 2012 Mar;15(1):56-62. doi: 10.1038/pcan.2011.36. Epub 2011 Aug 2.

PMID:
21808286
49.

Outcomes of arteriovenous fistula creation after the Fistula First Initiative.

Schinstock CA, Albright RC, Williams AW, Dillon JJ, Bergstralh EJ, Jenson BM, McCarthy JT, Nath KA.

Clin J Am Soc Nephrol. 2011 Aug;6(8):1996-2002. doi: 10.2215/CJN.11251210. Epub 2011 Jul 7.

50.

Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer.

Boorjian SA, Karnes RJ, Viterbo R, Rangel LJ, Bergstralh EJ, Horwitz EM, Blute ML, Buyyounouski MK.

Cancer. 2011 Jul 1;117(13):2883-91. doi: 10.1002/cncr.25900. Epub 2011 Jan 10.

Supplemental Content

Loading ...
Support Center